Hospital
Russell Hospital Corporation
Russell Hospital Corporation was paid $3.55M by Medicaid between Jan 2018 and Nov 2024, across 101 billing codes. Its largest line is 99285, emergency room visit (most serious) — 30% of everything it billed.
33Billing provider infoRUSSELL HOSPITAL CORPORATION
ALEXANDER CITY, AL 35010
ALEXANDER CITY, AL 35010
33aNPI1811913460assigned 07/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.55M
24GClaims129,435
24DCodes billed101
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#20 of 77
Median peer was paid$1.13M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,568 | $466K | |
| 2019 | 25,274 | $558K | |
| 2020 | 15,919 | $461K | |
| 2021 | 22,442 | $509K | |
| 2022 | 17,701 | $499K | |
| 2023 | 15,982 | $598K | |
| 2024incomplete | 11,549 | $459K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 5,300 | 4,705 | $1.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 10,256 | 9,309 | $639K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 13,288 | 12,197 | $508K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.4% | 3,817 | 3,508 | $157K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.7% | 4,092 | 3,869 | $133K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 4,700 | 4,425 | $102K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.6% | 4,045 | 3,372 | $94K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.5% | 1,752 | 1,568 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 9,443 | 8,223 | $69K |
| 80053 | Comprehensive metabolic panel | 1.9% | 7,623 | 6,662 | $69K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.5% | 974 | 880 | $55K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 3,855 | 3,102 | $45K |
89 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 266 | $42K |
| 87449 | 1.1% | 2,561 | $39K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 474 | $27K |
| 81001 | <1% | 8,021 | $27K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 192 | $26K |
| 85027 | <1% | 4,592 | $24K | |
| 97597 | <1% | 2,274 | $23K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 59 | $21K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 413 | $21K |
| 86762 | <1% | 903 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,298 | $18K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,011 | $16K |
| 83020 | <1% | 863 | $15K | |
| 86592 | <1% | 2,246 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,990 | $13K |
| 87340 | <1% | 903 | $12K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 326 | $12K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 282 | $11K |
| 82728 | <1% | 975 | $10K | |
| 88142 | <1% | 339 | $9K | |
| 86850 | <1% | 1,426 | $9K | |
| 86701 | <1% | 709 | $8K | |
| 82950 | <1% | 1,102 | $7K | |
| 87070 | <1% | 896 | $7K | |
| 81025 | <1% | 1,613 | $5K | |
| 84484 | <1% | 1,019 | $5K | |
| 89230 | <1% | 421 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 174 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 149 | $4K |
| 86803 | <1% | 241 | $4K | |
| 86901 | <1% | 1,517 | $4K | |
| 87186 | <1% | 506 | $4K | |
| 86900 | <1% | 1,388 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 134 | $4K |
| 83690 | <1% | 624 | $3K | |
| 84144 | <1% | 208 | $3K | |
| 87807 | <1% | 231 | $3K | |
| 0002A | <1% | 78 | $3K | |
| 0001A | <1% | 74 | $2K | |
| 87634 | <1% | 42 | $2K | |
| 82150 | <1% | 386 | $2K | |
| 83735 | <1% | 380 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 81 | $2K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 72 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 135 | $1K |
| 83615 | <1% | 204 | $1K | |
| 84550 | <1% | 204 | $1K | |
| 83605 | <1% | 142 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 380 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,436 | $1K |
| 43249 | <1% | 13 | $1K | |
| 59025 | Fetal non-stress test | <1% | 226 | $970.80 |
| 82570 | <1% | 156 | $917.00 | |
| 84156 | <1% | 237 | $911.89 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,394 | $827.13 |
| 84439 | <1% | 68 | $731.34 | |
| 80061 | Lipid panel | <1% | 45 | $680.55 |
| 85610 | <1% | 230 | $513.53 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 118 | $493.20 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 631 | $486.53 |
| 84681 | <1% | 39 | $433.29 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32 | $381.78 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 43 | $323.52 |
| 87081 | <1% | 24 | $320.40 | |
| 87205 | <1% | 257 | $295.35 | |
| 82105 | <1% | 13 | $242.11 | |
| 74022 | <1% | 13 | $228.33 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 759 | $212.75 |
| 85730 | <1% | 187 | $210.24 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 534 | $187.00 |
| 82550 | <1% | 29 | $182.40 | |
| 82947 | <1% | 34 | $180.12 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 466 | $180.00 |
| 73564 | <1% | 19 | $150.40 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 363 | $143.00 |
| 82553 | <1% | 12 | $102.06 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 27 | $99.60 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $89.80 |
| 87040 | <1% | 14 | $70.77 | |
| 85379 | <1% | 12 | $67.38 | |
| 87077 | <1% | 17 | $17.96 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 258 | $7.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $6.48 |
| A9270 | Non-covered item or service | 0% | 92 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 27 | $0.00 |
| 81511 | 0% | 15 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 44 | $0.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 3,746 | $0.00 |
| 0598T | 0% | 112 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEACE, LOTHER (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Russell Hospital Corporation | Alexander City, AL | $596K |
| The Russell Hospital Corporation | Goodwater, AL | $221K |
| Russell Hospital Corporation | Alexander City, AL | $109K |
| The Russell Hospital Corporation | New Site, AL | $84K |
| The Russell Hospital Corporation | Dadeville, AL | $19K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.